Apollo Cancer Centre Achieves Milestone in CAR T-Cell Therapy

Strategic Insights -

Apollo Cancer Centre (ACC) in Navi Mumbai has successfully treated two patients with made-in-India CAR T-cell therapy, marking a significant milestone in the hospital's commitment to delivering high-quality, life-saving transplant services.

The centre has seen remarkable success with 85 Bone Marrow Transplant (BMT) procedures, with a long-term success rate of over 70%. The recent CAR T-cell procedures, including cases of international patients, highlight the hospital's dedication to providing advanced cancer care.

Key Takeaways:

  • Apollo Cancer Centre (ACC) has successfully treated 2 patients with made-in-India CAR T-cell therapy, a breakthrough immunotherapy that uses patients' own genetically modified immune cells to target and destroy cancer.
  • The hospital has achieved a remarkable success rate of over 70% in 85 Bone Marrow Transplant (BMT) procedures, treating both adult and pediatric patients, including international cases.
  • The CAR T-cell therapy was administered to two patients, Mrs. Sharma (49 yrs) and Mr. Das (57 yrs), who were suffering from blood cancer and follicular lymphoma, respectively.
  • The treatment involved collecting and modifying patients' immune cells to express modified connectors on their surface to better recognize and attack cancer.
  • Both patients received chemotherapy before the infusion and were treated for fever and low blood cell counts after the therapy.
  • The hospital's Senior Consultant, Dr. Punit Jain, highlighted the potential of CAR T-cell therapy in rewriting what's possible for patients with blood cancers who have relapsed on conventional treatment.
  • Mr. Arunesh Punetha, Regional CEO of Apollo Hospitals, emphasized the centre's commitment to offering advanced cancer care in India, having successfully performed CAR T-cell procedures in several other ACCs.

Statistics:

  • 85 successful Bone Marrow Transplant (BMT) procedures
  • BMT success rate: over 70%
  • Successful CAR T-cell therapies: 2
  • Timeframe for CAR T-cell therapy administration: May and June 2025
  • Number of patients treated: 2 (Mrs. Sharma and Mr. Das)

Sources:

  • PRNewswire, "Apollo Cancer Centre (ACC) Successfully Treats Two Patients with Made-in-India CAR T-Cell Therapy" (September 4, 2025)
  • Apollo Cancer Centre, Navi Mumbai

Please note that the provided information is specific to the given text and may not reflect current data or developments.